Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?
J Neurol
; 268(11): 3975-3979, 2021 Nov.
Article
in English
| MEDLINE | ID: covidwho-1182249
ABSTRACT
During the COVID-19 pandemic, concerns raised regarding the use of immunosuppressants in multiple sclerosis, even if current data do not support an increased risk of infection. Although fingolimod can be temporarily suspended during COVID-19, the benefit-risk balance of suspension can be challenging. Till now, no adverse events have been described after the resumption of fingolimod, following a previous discontinuation. We report the occurrence of atrioventricular block following fingolimod restart. Fingolimod acts on sphingosine-1-phosphate-axis, a pathway that is altered with COVID-19 and hypoxic conditions. Herein we discuss how these metabolic changes may have influenced fingolimod pharmacology leading to a cardiac event.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Atrioventricular Block
/
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Neurol
Year:
2021
Document Type:
Article
Affiliation country:
S00415-021-10556-z
Similar
MEDLINE
...
LILACS
LIS